Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Economic burden of hepatitis C infection
The studies of economic burden of chronic diseases have generally been falling behind
similar studies related to their epidemiology, morbidity, and mortality. 1 However …
similar studies related to their epidemiology, morbidity, and mortality. 1 However …
Systematic review: cost‐effectiveness of direct‐acting antivirals for treatment of hepatitis C genotypes 2‐6
Background The availability of direct‐acting antivirals (DAA s) has dramatically changed the
landscape of hepatitis C virus (HCV) therapy; however, the cost and budget requirements for …
landscape of hepatitis C virus (HCV) therapy; however, the cost and budget requirements for …
Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients
R Juanbeltz, I Martínez-Baz, R San Miguel… - PloS one, 2018 - journals.plos.org
Background Direct-acting antivirals (DAA) have demonstrated high efficacy to achieve
sustained virological response (SVR) in chronic hepatitis C patients. We aim to assess the …
sustained virological response (SVR) in chronic hepatitis C patients. We aim to assess the …
Medicaid reimbursement for oral direct antiviral agents for the treatment of chronic hepatitis C
K Ooka, JJ Connolly, JK Lim - … journal of the American College of …, 2017 - journals.lww.com
Background All-oral direct-acting antiviral (DAA) regimens are an excellent modality to treat
chronic hepatitis C virus (HCV) infection. Federal Medicaid law requires states to cover all …
chronic hepatitis C virus (HCV) infection. Federal Medicaid law requires states to cover all …
Population health and cost-effectiveness implications of a “treat all” recommendation for HCV: a review of the model-based evidence
The World Health Organization HCV Guideline Development Group is considering a “treat
all” recommendation for persons infected with hepatitis C virus (HCV). We reviewed the …
all” recommendation for persons infected with hepatitis C virus (HCV). We reviewed the …
[PDF][PDF] Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals
J Mar, O Ibarrondo, I Martinez-Baz… - Rev Esp Enferm …, 2018 - researchgate.net
The high initial cost of antivirals against hepatitis C prompted development of the “Strategic
Plan for Tackling Chronic Hepatitis C in the Spanish National Health System”. The objective …
Plan for Tackling Chronic Hepatitis C in the Spanish National Health System”. The objective …
Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain
J Turnes, R Domínguez-Hernández… - … y Hepatología (English …, 2017 - Elsevier
Objective To evaluate the cost-effectiveness of a strategy based on direct-acting antivirals
(DAAs) following the marketing of simeprevir and sofosbuvir (post-DAA) versus a pre-direct …
(DAAs) following the marketing of simeprevir and sofosbuvir (post-DAA) versus a pre-direct …
Systematic review of health state utility values used in European pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness results
R Han, C François, M Toumi - Applied health economics and health policy, 2021 - Springer
Background Health state utility values (HSUVs) identified from utility elicitation studies are
widely used in pharmacoeconomic evaluations for chronic hepatitis C (CHC) and are …
widely used in pharmacoeconomic evaluations for chronic hepatitis C (CHC) and are …
Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review
Introduction: High prices of second-generation direct-acting antivirals (DAAs) in the
treatment of chronic hepatitis C virus (HCV) patients led to reimbursement decisions based …
treatment of chronic hepatitis C virus (HCV) patients led to reimbursement decisions based …
Economic evaluation of direct-acting antivirals for hepatitis C in Norway
Purpose New direct-acting antiviral (DAA) drugs have revolutionized the treatment of
hepatitis C in recent years. Objective Our objective was to analyse the cost effectiveness of …
hepatitis C in recent years. Objective Our objective was to analyse the cost effectiveness of …